Biostock publishes an article about the key milestone toward commercialisation – assay design freeze
Biostock publishes an article about Prolight Diagnostics has reached high-sensitivity troponin assay design freeze, locking in the final chemical configuration and performance characteristics. This marks a transition from the development phase to manufacturing optimization, setting the stage for the upcoming clinical performance study. Read the full article here: https://biostock.se/en/2025/12/prolight-diagnostics-nar-assay-design-freeze-for-det-hogkansliga-troponintestet-en-avgorande-milstolpe-for-psyros/ For further information, please contact:Ulf Bladin, […]
Prolight Diagnostics achieves assay design freeze for Psyros™ point-of-care cartridge – A key milestone toward commercialisation
Prolight Diagnostics today announced it has reached assay design freeze for its Psyros™ point-of-care cartridge, marking a major development milestone for the Psyros platform and an important step toward commercialisation. The design freeze confirms the final assay configuration and performance characteristics, freezing the cartridge chemistry. With this milestone achieved, Prolight can now transition to the […]
Prolight secures third patent in Europe for Psyros™
Prolight Diagnostics announces today that its third European patent for the Psyros single-molecule-counting technology has been granted in Europe by the European Patent Office (EPO), bringing the total number of patents granted in 2025 to three for the Psyros technology. The third patent is valid until 2042. “We are delighted that the EPO have granted another patent […]
BioStock publishes an article describing how Prolight Diagnostics is preparing the clinical study
BioStock publishes an article describing how Prolight Diagnostics is preparing the clinical study that will form the basis for the launch of the company’s high-sensitivity point of care troponin assay. Read the full article here: https://biostock.se/en/2025/12/prolights-cto-satter-fokus-pa-cro-partnern-mdx/ For further information, please contact:Ulf Bladin, CEOE-mail: info@prolightdx.comPhone: +46 73 582 39 87Company website: www.prolightdx.com About UsProlight Diagnostics AB […]
THE NOMINATION COMMITTEE APPOINTED FOR THE ANNUAL GENERAL MEETING 2026
The nomination committee is appointed in consultation with the three largest shareholders or owner groups, according to the number of votes based on shareholder statistics from Euroclear Sweden, and other reliable owner information in accordance with the decision of the Annual General Meeting. The nomination committee’s task is to produce proposals for the AGM regarding the […]
Prolight announces timetable for share reverse split
The extraordinary general meeting in Prolight Diagnostics AB (publ) on 19 November 2025, resolved on a reverse share split of 1:100, whereby one hundred (100) existing shares will be consolidated into one (1) new share. The extraordinary general meeting authorised the board of directors to determine the record date for the reverse share split. The […]
BioStock publishes article about Prolight Diagnostics continued preparations to bring the Psyros platform to market
Read the full article here: https://biostock.se/en/2025/11/slutjusteringar-och-validering-i-fokus-hos-prolight-diagnostics-2/ For further information, please contact:Ulf Bladin, CEOE-mail: info@prolightdx.comPhone: +46 73 582 39 87Company website: www.prolightdx.com About UsProlight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems […]
Prolight Diagnostics publishes investor letter for November 2025
The investor letter notes, among other things that Prolight takes clear steps toward commercialization of the Psyros™ POC system. The investor letter is available via the attached file or on the company’s website: https://prolightdx.com/en/mediaeng/investor-letters/ For further information, please contact:Ulf Bladin, CEOE-mail: info@prolightdx.comPhone: +46 73 582 39 87Company website: www.prolightdx.com About UsProlight Diagnostics AB develops innovative […]
Emergers publishes updated analysis for Prolight Diagnostics
Emergers has updated its analysis of Prolight Diagnostics, noting among other things that the investment case has strengthened due to the fully subscribed rights issue and strong international interest following the presentation of the fully operational commercial prototype at the international ADLM congress in the US. Read the article here: https://www.emergers.se/prolight-m25/ For further information, please contact:Ulf […]
Prolight receives Notice of Intention to Grant in Europe for third Psyros™ patent
Prolight Diagnostics announces today that the European Patent Office (EPO) has issued a Notice of Intention to Grant for the company’s third patent application related to its proprietary Psyros™single-molecule-counting technology. This is the third PsyrosTM patent to be granted by the EPO in 2025. “We are delighted to receive confirmation that the EPO intends to […]